Mirum Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Mirum Pharmaceuticals has a total shareholder equity of $229.0M and total debt of $307.2M, which brings its debt-to-equity ratio to 134.2%. Its total assets and total liabilities are $660.8M and $431.8M respectively.
Belangrijke informatie
134.2%
Verhouding schuld/eigen vermogen
US$307.24m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$278.37m |
| Aandelen | US$228.99m |
| Totaal verplichtingen | US$431.77m |
| Totaal activa | US$660.75m |
Recente financiële gezondheidsupdates
Recent updates
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Analyse van de financiële positie
Kortlopende schulden: MIRM's short term assets ($367.8M) exceed its short term liabilities ($112.3M).
Langlopende schulden: MIRM's short term assets ($367.8M) exceed its long term liabilities ($319.5M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MIRM's net debt to equity ratio (12.6%) is considered satisfactory.
Schuld verminderen: MIRM's debt to equity ratio has increased from 0.9% to 134.2% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: MIRM has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if MIRM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.